The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Other products in this section:
Become an Insider to get the story behind the story — and before anyone else.
If we weren’t the first industrial civilization on Earth, would we ever know?
Fossils and objects are unlikely to survive more than a few million years. Searching for chemical traces of industrialization offers an intriguing alternative.
Gene therapy could free some people from a lifetime of blood transfusions
Correcting a genetic mutation lets beta thalassemia patients make healthy blood cells.
Pet cloning is bringing human cloning a little bit closer
People are copying pets to preserve a physical, and spiritual, connection to dead children.